SCHEMBL16711554

SCHEMBL16711554

CN1CCCc2c1nc(N1CCN(Cc3ncc(C(F)(F)F)cn3)CC1)[nH]c2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 20/20 1.00
▸ PARP1 P09874 20/20 1.00
▸ TNKS2 Q9H2K2 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16704057 0.89 TNKS (1.00) TNKSPARP1TNKS2
SCHEMBL16711551 0.88 TNKS (1.00) TNKSPARP1TNKS2
SCHEMBL16711555 0.87 TNKS (1.00) TNKSPARP1TNKS2
SCHEMBL16702018 0.86 TNKS (1.00) TNKSPARP1TNKS2
SCHEMBL16711549 0.84 TNKS (1.00) TNKSPARP1TNKS2
SCHEMBL18037769 0.82 TNKS (0.81) TNKSPARP1TNKS2
SCHEMBL16711557 0.80 TNKS (1.00) TNKSPARP1TNKS2
SCHEMBL16711634 0.80 TNKS (0.79) TNKSPARP1TNKS2
SCHEMBL16711552 0.80 TNKS (1.00) TNKSPARP1TNKS2
Hydrochloric Acid SCHEMBL18037771 0.79 TNKS (0.98) TNKSPARP1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3066099-B1 PYRIDO[2,3-D]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS LILLY CO ELI (US) 2017-09-06 — — EP disclosed
EP-3066099-B1 PYRIDO[2,3-D]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS LILLY CO ELI (US) 2017-09-06 — — EP disclosed
US-9624218-B2 Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors ELI LILLY AND COMPANY (US) 2017-04-18 — — US disclosed
US-9624218-B2 Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors ELI LILLY AND COMPANY (US) 2017-04-18 — — US disclosed
US-20160251348-A1 PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS ELI LILLY AND COMPANY 2016-09-01 — — US disclosed
US-20160251348-A1 PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS ELI LILLY AND COMPANY 2016-09-01 — — US disclosed
WO-2015069512-A1 PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS ELI LILLY AND COMPANY (US) 2015-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251348-A1 PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS TNKS, TYMP, TNKS1BP1 TNKS 1/4885PARP1 162/4885TNKS2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback